From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Naval G. Daver, MD; Amir Fathi, MD; Guillermo Garcia-Manero, MD; and Aditi Shastri, MD, discuss current applications for menin inhibitors in patients with acute leukemia, combination approaches under investigation, and managing treatment-related adverse events with menin inhibitors.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the latest efficacy and safety of menin inhibitors in the treatment of patients with KMT2A-rearranged and NPM1-mutated relapsed/refractory AML
• Apply recommended strategies to mitigate and manage adverse events associated with menin inhibitors in patients with AML

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Kura Oncology and Syndax Pharmaceuticals, Inc.

Chair:

Naval G. Daver, MD

Professor of Medicine
Co-Lead, Section of AML
Director, Leukemia Research Alliance Program
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Naval G. Daver, MD, has no relevant financial relationships with ineligible companies.

Faculty:

Amir Fathi, MD

Professor of Medicine
Harvard Medical School
Program Director, Center for Leukemia
Massachusetts General Hospital
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Autolus, Bristol Myers Squibb, Daiichi Sankyo, Genmab, Kura, Novartis, Pfizer, Prelude, Remix, Schrödinger, Servier, Syndax, Takeda, ThermoFisher; Grant/Research Funding: AbbVie, Bristol Myers Squibb, Kura, Servier

Guillermo Garcia-Manero, MD

Professor and Chair, ad interim
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Funding: Research Support: AbbVie, Ascentage, AstraZeneca, Bristol Myers Squibb, Chordia, Curis, Genentech, GSK, Novartis, Rigel, Servier, Taiho, Takeda, Zentalis

Aditi Shastri, MD

Attending Physician, Department of Oncology, Division of Hematological Malignancies, Cellular Therapy, and Bone Marrow Transplant
Associate Professor of Oncology, Medicine, and Developmental & Molecular Biology
Director, Clonal Hematopoiesis and Myelodysplastic Syndromes Clinics
Associate Director, Translational Research, Blood Cancer Institute
Montefiore Einstein Comprehensive Cancer Center
Bronx, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Geron, Kymera Therapeutics, Ryvu Therapeutics; Grant/Research Funding: Kymera Therapeutics, Ryvu Therapeutics; Other: Data Safety Monitoring Board Chair for Servier Pharmaceuticals

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on current and future applications of menin inhibitors in patients with acute leukemia, go to https://www.gotoper.com/molecularinsights26menin-activity.

Release Date

April 27, 2026

Expiration Date

April 27, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.